-
Mashup Score: 3
This webinar will include a sampling of patient advocate research abstracts from presented at the 2023 IASLC World Conference on Lung Cancer (WCLC23) in Singapo …
Source: www.iaslc.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 12023 WCLC Highlights | IASLC - 7 month(s) ago
Dr. Navneet Singh, MD DM (India) will moderate the program and lead the discussion and Q&A following panel presentations by Christian Rolfo, MD, Ph.D., MBA (USA …
Source: www.iaslc.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0FLAURA2 Trial Osimertinib Plus Chemotherapy Improves Outcomes in Advanced EGFR-Positive NSCLC - The ASCO Post - 7 month(s) ago
First-line treatment with osimertinib plus platinum-based chemotherapy achieved a statistically significant and clinically meaningful progression-free survival improvement compared with osimertinib alone in patients with advanced epidermal growth factor receptor (EGFR) -mutated non–small cell lung cancer (NSCLC), according to the findings of the phase III FLAURA2 study. These results were presented by Pasi A. Jänne, MD, PhD, of the Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston,
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0An overview of video-assisted thoracic surgery (VATS) - 7 month(s) ago
Alan Sihoe, MBBChir, FRCSEd, FCSHK, FHKAM, The University of Hong Kong, Pokfulam, Hong Kong, shares an overview and the benefits of video-assisted thoracic surgery (VATS) for lung cancer management. VATS is a modern minimally invasive surgery that has been beneficial for lung cancer patients who are usually ineligible for surgical therapies. Current goals are to make the surgery less invasive and to ensure enhanced recovery after surgery (ERAS). VATS can also complement pharmacological advances as the time between the procedure and post-operative adjuvant therapy can be significantly reduced. Research has also revealed that circulating tumour (ct)-DNA after VATS may be a useful biomarker for survival, where a lower quantity of ct-DNA after the procedure is associated with better clinical outcomes in adjuvant immunotherapy. Dr Sihoe comments that surgeons are continuously finding useful roles for VATS in lung cancer management. This interview took place at the 2023 World Conference on L
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Seshiru Nakazawa MD PhD on NSCLC and Point Mutations as de Novo Oncogenic Drivers - The ASCO Post - 7 month(s) ago
Seshiru Nakazawa, MD, PhD, of Dana-F arber Cancer Institute, discusses activating the MET tyrosine kinase domain mutation, which has been identified as the sole oncogenic mutation in a small but significant subset of patients with non–small cell lung cancer (NSCLC). According to Dr. Nakazawa’s findings, this mutation is potentially targetable with currently available MET tyrosine kinase inhibitors. Yasir Y. Elamin, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 42023 WCLC Highlights | IASLC - 7 month(s) ago
Dr. Navneet Singh, MD DM (India) will moderate the program and lead the discussion and Q&A following panel presentations by Christian Rolfo, MD, Ph.D., MBA (USA …
Source: www.iaslc.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Gilberto de Lima Lopes Jr MD MBA on Lung Cancer Management Expert Update - The ASCO Post - 7 month(s) ago
Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, comments on four presentations from the 2023 World Conference on Lung Cancer for which he served as discussant: the global landscape of three types of lung cancer (squamous cell, adenocarcinoma, and small cell); findings from the Australian Registry and Biobank of Thoracic Cancers; the Registry of Genetic Alterations of Taiwan by comprehensive next-generation sequencing; and treatment decisions
Source: ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Ilias Houda MD PhD Candidate on Results of an EORTC Survey on NSCLC Resectability - The ASCO Post - 7 month(s) ago
Ilias Houda, MD, PhD Candidate, of A msterdam University Medical Centers, discusses the differing opinions of thoracic surgeons when it comes to resection for stage III non–small cell lung cancer (NSCLC). The international EORTC survey showed there is no consensus, although respondents were more likely to consider some stage III TNM combinations to be potentially resectable. Chee K. Lee, PhD, MBBS, of the University of Sydney, discusses findings of the ILLUMINATE study, which showed d urvalumab and
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Xiuning Le MD PhD on Update on the Use of Tepotinib to Treat an NSCLC Subset - The ASCO Post - 7 month(s) ago
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses resul ts of the VISION trial, the largest on-treatment liquid biopsy biomarker data set of a MET inhibitor in patients with MET exon 14 non–small cell lung cancer (NSCLC). Tepotinib showed durable efficacy in this population. Chee K. Lee, PhD, MBBS, of the University of Sydney, discusses findings of the ILLUMINATE study, which showed d urvalumab and tremelimumab with chemotherapy yielded antitumor activity in patients
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Gilberto de Lima Lopes Jr MD MBA on Lung Cancer Management Expert Update - The ASCO Post - 7 month(s) ago
Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, comments on four presentations from the 2023 World Conference on Lung Cancer for which he served as discussant: the global landscape of three types of lung cancer (squamous cell, adenocarcinoma, and small cell); findings from the Australian Registry and Biobank of Thoracic Cancers; the Registry of Genetic Alterations of Taiwan by comprehensive next-generation sequencing; and treatment decisions
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Join us for an IASLC/STARS webinar including sampling of patient advocate research abstracts presented during #WCLC23 & a live Q&A session moderated by #lungcancer patient/research advocate @JFreemanDaily: https://t.co/J8KHKBDcZ9 #LCSM @jillfeldman4 @BairdAM @ProjectBreath #LCSM https://t.co/cewKBNkojf